Rep. Josh Gottheimer Sells Off Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Tandem Diabetes Care, Inc. NASDAQ: TNDM. In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Tandem Diabetes Care stock on March 19th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 3/24/2025.
• Sold $1,001 - $15,000 in shares of Spotify Technology NYSE: SPOT on 3/24/2025.
• Sold $1,001 - $15,000 in shares of Flywire NASDAQ: FLYW on 3/19/2025.
• Sold $1,001 - $15,000 in shares of Disco OTCMKTS: DSCSY on 3/19/2025.
• Sold $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/19/2025.
• Sold $1,001 - $15,000 in shares of Diageo NYSE: DEO on 3/19/2025.
• Sold $1,001 - $15,000 in shares of Shopify NYSE: SHOP on 3/19/2025.
• Sold $1,001 - $15,000 in shares of Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk NYSE: TLK on 3/19/2025.
• Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 3/19/2025.
• Sold $1,001 - $15,000 in shares of D.R. Horton NYSE: DHI on 3/19/2025.

Tandem Diabetes Care Stock Performance

Shares of TNDM stock traded down $0.40 during trading on Friday, reaching $16.86. The company had a trading volume of 1,132,393 shares, compared to its average volume of 1,503,733. The company has a market capitalization of $1.12 billion, a PE ratio of -8.74 and a beta of 1.52. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The firm's 50 day simple moving average is $21.77 and its two-hundred day simple moving average is $30.12. Tandem Diabetes Care, Inc. has a one year low of $15.75 and a one year high of $53.69.

Insider Activity

In other news, COO Jean-Claude Kyrillos purchased 10,538 shares of the business's stock in a transaction dated Friday, March 7th. The shares were acquired at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at $190,948.56. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Tandem Diabetes Care

Several large investors have recently made changes to their positions in TNDM. Vanguard Group Inc. boosted its holdings in shares of Tandem Diabetes Care by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock worth $267,989,000 after acquiring an additional 77,451 shares in the last quarter. ArrowMark Colorado Holdings LLC raised its holdings in shares of Tandem Diabetes Care by 14.1% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock valued at $98,108,000 after buying an additional 337,026 shares during the last quarter. State Street Corp grew its holdings in Tandem Diabetes Care by 3.2% during the 3rd quarter. State Street Corp now owns 2,655,736 shares of the medical device company's stock worth $112,630,000 after acquiring an additional 83,172 shares during the last quarter. GW&K Investment Management LLC increased its position in Tandem Diabetes Care by 18.0% in the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock valued at $76,488,000 after acquiring an additional 323,674 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Tandem Diabetes Care by 189.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company's stock worth $59,830,000 after purchasing an additional 1,086,337 shares in the last quarter.

Analyst Ratings Changes

Several research firms recently issued reports on TNDM. The Goldman Sachs Group decreased their price objective on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Citigroup cut shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and decreased their price target for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. Royal Bank of Canada dropped their price objective on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Mizuho started coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They set a "neutral" rating and a $20.00 target price for the company. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $63.00 price target on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Nine equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Tandem Diabetes Care presently has an average rating of "Moderate Buy" and an average price target of $43.88.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.